PlainRecalls
FDA Drug Critical Class I Completed

Carboplatin Injection, 450 mg/45 mL (10 mg/mL), 45 mL, Cytotoxic Agent, Sterile, Multi-Dose Vial, Rx only, For IV Use, NDC 61703-339-50 (Hospira label) and NDC 61703-360-50 (Novaplus label), Hospira, Inc., Lake Forest, IL 60045, Product of Australia.

Reported: February 13, 2013 Initiated: November 8, 2012 #D-154-2013

Product Description

Carboplatin Injection, 450 mg/45 mL (10 mg/mL), 45 mL, Cytotoxic Agent, Sterile, Multi-Dose Vial, Rx only, For IV Use, NDC 61703-339-50 (Hospira label) and NDC 61703-360-50 (Novaplus label), Hospira, Inc., Lake Forest, IL 60045, Product of Australia.

Reason for Recall

Crystallization: Product is being recalled due to visible particulates identified during a retain sample inspection. Findings have identified the particles as Carboplatin crystals.

Details

Recalling Firm
Hospira Inc.
Units Affected
31,326 vials
Distribution
Nationwide and Puerto Rico.
Location
Lake Forest, IL

Frequently Asked Questions

What product was recalled?
Carboplatin Injection, 450 mg/45 mL (10 mg/mL), 45 mL, Cytotoxic Agent, Sterile, Multi-Dose Vial, Rx only, For IV Use, NDC 61703-339-50 (Hospira label) and NDC 61703-360-50 (Novaplus label), Hospira, Inc., Lake Forest, IL 60045, Product of Australia.. Recalled by Hospira Inc.. Units affected: 31,326 vials.
Why was this product recalled?
Crystallization: Product is being recalled due to visible particulates identified during a retain sample inspection. Findings have identified the particles as Carboplatin crystals.
Which agency issued this recall?
This recall was issued by the FDA Drug on February 13, 2013. Severity: Critical. Recall number: D-154-2013.